PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined SubgroupsL. H. Schmidt, Wolfgang Hartmann|PLoS ONE|2015Cited by 228
SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemiaConstanze Schneider, Jindřich Činátl, Christoph Schliemann et al.|Nature Medicine|2016Cited by 185
Cooperation of cancer drivers with regulatory germline variants shapes clinical outcomesJulian Musa, Thomas G. P. Grünewald, Florencia Cidre‐Aranaz et al.|Nature Communications|2019Cited by 72
Phosphatidylinositol‐3′‐kinase/AKT signaling is essential in synovial sarcomaNicolaus Friedrichs, Wolfgang Hartmann|International Journal of Cancer|2010Cited by 52
<scp>SRC</scp> inhibition represents a potential therapeutic strategy in liposarcomaElisabeth Sievers, Wolfgang Hartmann|International Journal of Cancer|2015Cited by 24